Prime-boost vaccinations using recombinant flavivirus replicon and vaccinia virus vaccines: An ELISPOT analysis

Immunology and Cell Biology

Volumn 89, Issue 3, 2011, Pages 426-436

  Rattanasena, Paweena ^a,b,d   Anraku, Itaru ^a   Gardner, Joy ^a   Le, Thuy T ^a   Wang, Xiang Ju ^b   Khromykh, Alexander A ^c   Suhrbier, Andreas ^a,b,e  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d MAHASARAKHAM UNIVERSITY   (Thailand)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

ELISPOT; prime boost; replicon; vaccinia

Indexed keywords

DNA VACCINE; EPITOPE; GAMMA INTERFERON; VACCINIA VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLAVIVIRUS; IMMUNOMODULATION; MOUSE; NONHUMAN; REPLICON; TREATMENT OUTCOME; VACCINATION; VACCINIA VIRUS; VIRUS CHARACTERIZATION; VIRUS LIKE AGENT;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC VECTORS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; VACCINATION; VACCINES, DNA; VACCINES, VIRUS-LIKE PARTICLE; VACCINIA VIRUS; VIRAL VACCINES; WEST NILE VIRUS;

FLAVIVIRUS; MURINAE; POXVIRIDAE; VACCINIA VIRUS;

EID: 79952815659     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.99     Document Type: Article

References (77)

1. Ranasinghe C, Ramshaw IA. Genetic heterologous prime-boost vaccination stra-tegies for improved systemic and mucosal immunity. Expert Rev Vaccines 2009; 8: 1171-1181.
2. Radosevic K, Rodriguez A, Lemckert A, Goudsmit J. Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert Rev Vaccines 2009; 8: 577-592.
3. Kutzler MA, Weiner DB. DNAvaccines: readyfor primetime? Nat Rev Genet 2008; 9: 776-788.
4. Adamina M, Weber WP, Rosenthal R, Schumacher R, Zajac P, Guller U et al. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial. Contemp Clin Trials 2008; 29: 165-181. (Pubitemid 351255516)
5. Schneider J, Gilbert SC, Hannan CM, Degano P, Prieur E, Sheu EG et al. Induction of CD8+ Tcells using heterologous prime-boost immunisation strategies. Immunol Rev 1999; 170: 29-38. (Pubitemid 29490742)
6. Lu S. Heterologousprime-boostvaccination. Curr Opin Immunol 2009;21: 346-351.
7. Harari A, Bart PA, Stohr WF, Tapia G, Garcia M, Medjitna-Rais E et al. An HIV-1 cladeC DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting Tcell responses. J Exp Med 2008; 205: 63-77. (Pubitemid 351185716)
8. Cristillo AD, Lisziewicz J, He L, Lori F, Galmin L, Trocio JN et al. HIV-1 prophylactic vaccine comprised of topical Derma Vir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 2007; 366: 197-211. (Pubitemid 47314400)
9. Sun Y, Schmitz JE, Buzby AP, Barker BR, Rao SS, Xu L et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 2006; 80: 10950-10956. (Pubitemid 44706536)
10. Vaccari M, Trindade CJ, Venzon D, Zanetti M, Franchini G. Vaccine-induced CD8(+) central memory T cells in protection from simian AIDS. J Immunol 2005; 175: 3502-3507. (Pubitemid 41292007)
11. Woodberry T, Gardner J, Elliott SL, Leyrer S, Purdie DM, Chaplin P et al. Prime boost vaccination strategies: CD8 Tcell numbers, protection, and Th1 bias. J Immunol 2003; 170: 2599-2604. (Pubitemid 36245651)
12. Weiss R, Scheiblhofer S, Thalhamer J. DNA vaccines for allergy treatment. Methods Mol Med 2006; 127: 253-267.
13. Brave A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K et al. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther 2007; 15: 1724-1733. (Pubitemid 47289017)
14. Otten G, Schaefer M, Greer C, Calderon-Cacia M, Coit D, Kazzaz J et al. Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylac-tide coglycolide microparticles. J Virol 2003; 77: 6087-6092. (Pubitemid 36539001)
15. Letvin NL Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006; 6: 930-939. (Pubitemid 44851735)
16. Weiss RA. Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges. Clin Exp Immunol 2008; 152: 201-210. (Pubitemid 351520921)
17. Cox KS, Clair JH, Prokop MT, Sykes KJ, Dubey SA, Shiver JW et al. DNAgag/adenovirus type5 (Ad5)gagand Ad5gag/Ad5 gagvaccines inducedistinctT-cell responseprofiles. J Virol 2008; 82: 8161-8171.
18. Cottingham MG, van Maurik A, Zago M, Newton AT, Anderson RJ, Howard MK et al. Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies. Clin Vaccine Immunol 2006; 13: 747-757.
19. Santra S, Sun Y, Parvani JG, Philippon V, Wyand MS, Manson K et al. Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. J Virol 2007; 81: 8563-8570. (Pubitemid 47242829)
20. Naslund TI, Uyttenhove C, Nordstrom EK, Colau D, Warnier G, Jondal M et al. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVACvectorsdemonstratedifferences in thegeneration of a protectivecentral memory CTL response against the P815 tumor. J Immunol 2007; 178: 6761-6769. (Pubitemid 46847400)
21. Lin CT, Hung CF, Juang J, He LM, Lin KY, Kim TW et al. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther 2003; 8: 559-566. (Pubitemid 37321684)
22. Vazquez-Blomquist D, Quintana D, Duarte CA. Modified-vaccinia-virus- Ankara (MVA) primingandfowlpox-virus boosterelicit astrongerCD8+T-cell response in miceagainst an HIV-1 epitope than does a DNA/poxvirus prime-booster approach. Biotechnol Appl Biochem 2004; 39: 313-318. (Pubitemid 38788094)
23. Anderson RJ, Hannan CM, Gilbert SC, Laidlaw SM, Sheu EG, Korten S et al. Enhanced CD8+ Tcell immune responses and protection elicited against Plasmodium Berghei malaria by prime boost immunization regimens usinga novel attenuated Fowlpoxvirus. J Immunol 2004; 172: 3094-3100. (Pubitemid 38263699)
24. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthyvolunteers. J Immunol 2005; 174: 449-455. (Pubitemid 40007434)
25. Anraku I, Mokhonov VV, Rattanasena P, Mokhonova EI, Leung J, Pijlman G et al. Kunjin replicon-based simian immunodeficiency virus gag vaccines. Vaccine 2008; 26: 3268-3276.
26. Anraku I, Harvey TJ, Linedale R, Gardner J, Harrich D, Suhrbier A et al. Kunjin virus replicon vaccine vectors induce protective CD8(+) T-cell immunity. J Virol 2002; 76: 3791-3799. (Pubitemid 34250544)
27. Pijlman GP, Suhrbier A, Khromykh AA. Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin Biol Ther 2006; 6: 135-145. (Pubitemid 43259894)
28. Yun SI, Song BH, Koo Y, Jeon I, Byun SJ, Park JH et al. Japanese encephalitis virus-based replicon RNAs/particlesasan expression system for HIV-1 Pr55 Gagthat is capable of producing virus-like particles. Virus Res 2009; 144: 298-305.
29. Khromykh AA. Replicon-based vectors of positive strand RNA viruses. Curr Opin Mol Ther 2000; 2: 555-569.
30. Atkins GJ, Fleeton MN, Sheahan BJ. Therapeutic and prophylactic applications of alphavirusvectors. Expert Rev Mol Med 2008; 10: e33.
31. Zhao HP, Sun JF, Li N, Sun Y, Wang Y, Qiu HJ. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice. Vet Immunol Immunopathol 2009; 131: 158-166.
32. Chen L, Ewing D, Subramanian H, Block K, Rayner J, Alterson KD et al. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaquesv. J Virol 2007; 81: 11634-11639. (Pubitemid 47623795)
33. Barefoot B, Thornburg NJ, Barouch DH, Yu JS, Sample C, Johnston RE et al. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 2008; 26: 6108-6118.
34. Thomson SA, Sherritt MA, Medveczky J, Elliott SL, Moss DJ, Fernando GJ et al. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol 1998; 160: 1717-1723. (Pubitemid 28106457)
35. Thomson SA, Khanna R, Gardner J, Burrows SR, Coupar B, Moss DJ et al. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci USA 1995; 92: 5845-5849.
36. Beverley PC Primer: making sense of T-cell memory. Nat Clin Pract Rheumatol 2008; 4: 43-49.
37. Ahmed R, Bevan MJ, Reiner SL, Fearon DT. The precursors of memory: models and controversies. Nat Rev Immunol 2009; 9: 662-668.
38. Harty JT, Badovinac VP. Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol 2008; 8: 107-119. (Pubitemid 351161304)
39. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15: 293-299.
40. Tscharke DC, Suhrbier A. From miceto humans murine intelligencefor human CD8(+) Tcell vaccine design. Expert Opin Biol Ther 2005; 5: 263-271. (Pubitemid 40388855)
41. Todryk SM, Pathan AA, Keating S, Porter DW, Berthoud T, Thompson F et al. The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology 2009; 128: 83-91.
42. Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J Infect Dis 2010; 201: 132-141.
43. Dangoor A, Lorigan P, Keilholz U, Schadendorf D, Harris A, Ottensmeier C et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dosepoly-epitopevaccine. Cancer Immunol Immunother 2009; 59: 863-873.
44. Streeck H, Frahm N, Walker BD. The roleof IFN-gamma ELISPOTassay in HIVvaccine research. Nat Protoc 2009; 4: 461-469.
45. Badovinac VP, Harty JT. Programming, demarcating, and manipulating CD8(+) T-cell memory. Immunol Rev 2006; 211: 67-80. (Pubitemid 43882962)
46. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A et al. Induction of multifunctional human immunodeficiencyvirustype 1 (HIV-1)-specificTcellscapable of proliferation in healthy subjects by using a prime-boost regimen of DNA-and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006; 80: 4717-4728.
47. Thomson SA, Elliott SL, Sherritt MA, Sproat KW, Coupar BEH, Scalzo AA et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol 1996; 157: 822-826. (Pubitemid 26231388)
48. De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, Thomson S et al. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol 2007; 81: 292-300. (Pubitemid 44975169)
49. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006; 24: 4554-4561. (Pubitemid 43776762)
50. Shephard E, Burgers WA, Van Harmelen JH, Monroe JE, Greenhalgh T, Williamson C et al. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res Hum Retroviruses 2008; 24: 207-217. (Pubitemid 351282110)
51. Cockburn IA, Chakravarty S, Overstreet MG, Garcia-Sastre A, Zavala F. Memory CD8(+) T cell responses expand when antigen presentation overcomes T cell self-regulation. J Immunol 2008; 180: 64-71.
52. D'Cruz LM, Rubinstein MP, Goldrath AW. Surviving the crash: transitioning from effector to memoryCD8+Tcell. Semin Immunol 2009; 21: 92-98.
53. Radaelli A, Nacsa J, Tsai WP, Edghill-Smith Y, Zanotto C, Elli V et al. Prior DNA immunization enhances immune responseto dominant and subdominantviral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infectedwithSIVmac251. Virology 2003; 312: 181-195. (Pubitemid 36918470)
54. Burgers WA, Chege GK, Muller TL, van Harmelen JH, Khoury G, Shephard EG et al. Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 2009; 90: 468-480.
55. Harrington LE, van der Most R, Whitton JL, Ahmed R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 2002; 76: 3329-3337. (Pubitemid 34224535)
56. Chen W, McCluskey J. Immunodominanceand immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv Cancer Res 2006; 95: 203-247. (Pubitemid 44066527)
57. Tscharke DC, Woo WP, Sakala IG, Sidney J, Sette A, Moss DJ et al. Poxvirus CD8+T-cell determinants and cross-reactivity in BALB/c mice. J Virol 2006; 80: 6318-6323. (Pubitemid 43927434)
58. Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP. Type I interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 2006; 24: 5110-5118. (Pubitemid 43818199)
59. Gomez CE, Najera JL, Krupa M, Esteban M. The poxvirus vectors MVA and NYVAC as genedeliverysystems forvaccination against infectiousdiseases and cancer. Curr Gene Ther 2008; 8: 97-120.
60. Ramos HJ, Davis AM, Cole AG, Schatzle JD, Forman J, Farrar JD. Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memoryT-cell fates. Blood 2009; 113: 5516-5525.
61. Amara RR, Villinger F, Staprans SI, Altman JD, Montefiori DC, Kozyr NL et al. Different patternsof immuneresponses butsimilar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002; 76: 7625-7631. (Pubitemid 34760986)
62. Barouch DH, Liu J, Lynch DM, O'Brien KL, La Porte A, Simmons NL et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol 2009; 83: 9584-9590.
63. Smith JM, Amara RR, Campbell D, Xu Y, Patel M, Sharma S et al. DNA/MVA vaccinefor HIVtype 1: effects of codon-optimization and the expression ofaggregates orvirus-like particles on the immunogenicityof the DNA prime. AIDS Res Hum Retroviruses 2004; 20: 1335-1347. (Pubitemid 40065929)
64. Someya K, Xin KQ, Matsuo K, Okuda K, Yamamoto N, Honda M. Aconsecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J Virol 2004; 78: 9842-9853. (Pubitemid 39187104)
65. Dale CJ, De Rose R, Stratov I, Chea S, Montefiori DC, Thomson S et al. Efficacyof DNA and fowlpoxvirus priming/boostingvaccinesfor simian/human immunodeficiencyvirus. J Virol 2004; 78: 13819-13828.
66. Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B et al. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009; 27: 4468-4474.
67. Steensels M, Bublot M, Van Borm S, DeVriese J, Lambrecht B, Richard-Mazet A et al. Prime-boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI. Vaccine 2009; 27: 646-654.
68. Koopman G, Mortier D, Hofman S, Niphuis H, Fagrouch Z, Norley S et al. Vaccine protection from CD4(+) T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIVantigens. J Gen Virol 2004; 85: 2915-2924. (Pubitemid 39360034)
69. Negri DRM, Baroncelli S, Catone S, Comini A, Michelini Z, Maggiorella MT et al. Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. J Gen Virol 2004; 85: 1191-1201. (Pubitemid 38659782)
70. Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinantvaccinia immunization caused by preexistingpoxvirus immunity. Proc Natl Acad Sci USA 1999; 96: 4512-4517. (Pubitemid 29190367)
71. Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002; 168: 4391-4398. (Pubitemid 34441339)
72. Bracci L, La Sorsa V, Belardelli F, Proietti E. Type I interferons as vaccine adjuvants against infectious diseases and cancer. Expert Rev Vaccines 2008; 7: 373-381. (Pubitemid 351520025)
73. Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 2008; 26: 333-344.
74. Albrecht M, Suezer Y, Staib C, Sutter G, Vieths S, Reese G. Vaccinationwith a modified vaccinia virus Ankara-based vaccine protects mice from allergic sensitization. J Gene Med 2008; 10: 1324-1333.
75. Harvey TJ, Liu WJ, Wang XJ, Linedale R, Jacobs M, Davidson A et al. Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. J Virol 2004; 78: 531-538. (Pubitemid 37549765)
76. Woodland DL. Jump-starting the immune system: prime-boostingcomesofage. Trends Immunol 2004; 25: 98-104.
77. Le TT, Gardner J, Hoang-Le D, Schmidt CW, MacDonald KP, Lambley E et al. Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies. Vaccine 2009; 27: 3053-3062.